HeartBeam

Total Heart Intelligence… Wherever You Are

FIRST QUARTER 2026 FINANCIAL RESULTS CONFERENCE CALL

MAY 13, 2026

NASDAQ: BEAT

Disclaimer

This presentation contains forward-looking statements. All statements other than statements of historical fact contained in this presentation, including statements as to the Company's future results of operations and financial position, planned products and services, business strategy and plans and objectives of management for future operations, are forward-looking statements.

These statements involve known and unknown risks, uncertainties, assumptions and other factors that may cause the Company's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements.

In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expects," "plans," anticipates," "could," "intends," "target," "projects," "contemplates," "believes," "estimates," "aims," "predicts," "potential," "seeks," attempts," "poised" or "continues" or the negative of these terms or other similar words. These statements are only predictions.

The Company has based these forward-looking statements largely on its current expectations and projections about future events and financial trends that it believes may affect its business, financial condition and results of operations. Also, these forward-looking statements represent the Company's estimates and assumptions only as of the date of this presentation. The Company assumes no obligation to update any forward-looking statements after the date of this presentation.

This presentation also contains estimates and other statistical data made by independent parties and by the Company relating to market size and growth and other industry data. This data involves several assumptions and limitations, and you are cautioned not to give undue weight to such estimates. The Company has not independently verified the statistical and other industry data generated by independent parties and contained in this presentation and, accordingly, it cannot guarantee their accuracy or completeness.

In addition, projections, assumptions and estimates of its future performance and the future performance of the industries in which it operates are necessarily subject to a high degree of uncertainty and risk due to a variety of factors. These and other factors could cause results to differ materially from those expressed in the estimates made by independent parties and by the Company. For additional risks and uncertainties that could impact the Company's forward-looking statements, please see disclosures contained in HeartBeam's public filings with the SEC, including the "Risk Factors" in HeartBeam's Annual Report on Form 10-K, and which may be viewed at www.sec.gov.

The HeartBeam System received FDA clearance for arrhythmia assessment in December 2024. The 12-Lead ECG synthesis software for arrhythmia assessment received FDA clearance in December 2025. Refer to the Company’s Cleared Indications for Use at https://www.heartbeam.com/indications for details on the intended use of its technology.

Agenda

WHAT WE'LL COVER:

- Q1 2026 and Recent Operational Highlights
- HeartBeam's Core Technology and Platform
- HeartBeam System: Limited Commercial Launch
- On-Demand 12-Lead ECG Patch
- Heart Attack Detection + AI
- Financials

ON THE CALL TODAY:

ROB ENO
Chief Executive Officer

TIM CRUICKSHANK
Chief Financial Officer

BRYAN HUMBARGER
Chief Commercial Officer

Q1 2026 and Recent Operational Highlights

Consistent execution on near-term goals while advancing our long-term growth strategy

Commercial Strategy	✓ Signed first commercial partnership with ClearCardio™, a rapidly growing preventive cardiology practice. Initial rollout in 3 key markets: NY metro, Dallas, South Florida. ✓ Signed commercial partnership with Atelier Health, a Beverly Hills-based premier concierge medical practice led by physicians affiliated with Cedars-Sinai.	➢ Established flagship commercial sites across four target markets: NY, Dallas, South Florida, Southern California. ➢ Initial foothold in structured direct pay healthcare segment, representing approx. 5 million U.S. patients.
Heart Attack Detection	✓ Enrolled first patients in ALIGN-ACS pilot study for heart attack detection. ✓ Study in emergency department. Enrolling ahead of schedule.	➢ Milestone signifies key step toward future FDA indication expansion for heart attack assessment. ➢ Future indication expansion would address over 20 million patients at risk of heart attack.
On-Demand 12-Lead Patch	✓ Completed first working prototype of an extended-wear 12-lead ECG ambulatory patch, designed to aid in detecting ischemia and complex arrythmias. ✓ Initiated pilot study of 12-Lead Patch to detect ischemia.	➢ Targets a $2 billion market with established reimbursement; ischemia detection has potential to disrupt the patch market currently limited to atrial fibrillation detection.
AI Program	✓ Announced strategic collaboration with Mount Sinai to support development and validation of next-generation AI-ECG algorithms.	➢ Combines Mount Sinai's AI and clinical expertise with HeartBeam's 3D ECG signal collection technology. ➢ Focused on future applications including heart attack detection and personalized cardiac assessment.

Ischemia, AI algorithm, and 12-Lead patch products not cleared by FDA and not available for sale in the United States or other geographies.

BRINGING CARE BEYOND THE HOSPITAL

A Cardiac Intelligence Platform…Anywhere.

Powered by FDA-cleared ECG technology.

HeartBeam is the **first ever cable-free device synthesized 12-Lead ECG platform for arrhythmia assessment,** delivering clinical-grade insights wherever symptoms occur.



One platform.
Two form factors.
Shared cardiac intelligence.

CORE PLATFORM



PATENTED 3D SIGNAL
COLLECTION TECHNOLOGY

FORM FACTORS

HEARTBEAM SYSTEM
CABLE-FREE 12-LEAD ECG
FOR AT-HOME USE

ON–DEMAND 12-LEAD PATCH
CONTINUOUS
1-LEAD → 12-LEAD
ON DEMAND

APPLICATIONS ENABLED

ARRHYTHMIA



HEART ATTACK DETECTION

PERSONALIZED AI ALGORITHMS

Heart attack detection, AI algorithm, and 12-Lead patch products not cleared by FDA and not available for sale in the United States or other geographies.

Clear Plan to Fuel the Next Stage of Growth

Goals remain consistent, execution of strategy underway

1ST HALF 2026

Validate premium value proposition

Refine HeartBeam systems and processes

Sign and onboard anchor accounts

Prove scaling efficiency

2ND HALF 2026

Prove deep adoption into anchor accounts

Establish funnel to support 2027 revenue and adoption goals

Develop white papers/proof points for future adoption

Expand sales team for regional growth

2027+

Scale revenue

Move to a train-the-trainer model for implementation

Expand clinical research opportunities

Full commercial team onboard

SCALING EFFICIENTLY WITHOUT THE NEED FOR A LARGE FIELD FORCE

One sale to a practice → enroll many patients

Fulfill inbound patient demand from anchor accounts

No DTC marketing spend

HIGH-MARGIN, SUBSCRIPTION BUSINESS WITH PATH TO BREAK-EVEN

70%+ margins on recurring revenue

Only 3-5 month payback period to cover year 1 upfront costs

Cash flow break-even at ~30,000 patients

Continued Execution on a **Focused Commercialization Strategy**



Goals established for 1st Half 2026:	Status:
✓ **Sign and onboard anchor accounts** in key, targeted markets	**Added Atelier Health**, premier concierge medicine practice led by physicians affiliated with Cedars-Sinai, and **expanded relationship with ClearCardio**
✓ Execute a concentrated rollout strategy in **four key geographies**	**Built flagship account presence** in New York, Dallas, South Florida and Southern California
✓ Validate our **premium value proposition**	Early physician engagement and flagship account traction reinforced **demand for personalized 12-lead ECG capability**
✓ Refine **physician workflows**	Worked directly with practices on **rollout planning, workflow integration and implementation processes**
Prove scaling efficiency	Demonstrating ability to **access large patient populations** through a focused set of strategically selected practices, with a very **lean commercial team**

HeartBeam's On-Demand 12-Lead ECG Patch: **Disrupting the Patch Market**

TODAY'S PATCH MARKET

Patch monitors are a $2B revenue market with existing reimbursement

Devices are 1-3 leads, which limit applications to arrhythmia detection and monitoring

Mobile Cardiac Telemetry (MCT) segment has highest reimbursement and fastest growth

HEARTBEAM ON-DEMAND 12-LEAD PATCH

Development of Working Prototype of Patch complete

Clinical grade 12-Lead ECG in a patch form factor

Continuous 1-Lead mode matches performance of existing systems

On-demand 12-Lead ECG mode **expands segment into ischemia detection**

Integrates into **existing clinical workflow**

Leverages existing **MCT reimbursement**

Ability to drive market share shifts and grow the market

https://www.reanin.com/reports/electrocardiograms-patch-and-holter-monitor-market
https://www.gminsights.com/pressrelease/wearable-cardiac-devices-market
12-Lead patch product not cleared by FDA and not available for sale in the United States or other geographies.

On-Demand 12-Lead ECG Patch: Building Significant Momentum

Targeting a $2 billion market with established reimbursement, the 12-Lead ECG Patch has the potential to disrupt the long-term continuous monitor and mobile cardiac telemetry (MCT) markets.

Initiated Pilot Study of Novel On-Demand 12-Lead ECG Patch to Detect Ischemia Outside the Clinic

- Significant step in the clinical and regulatory path for the patch
- First ambulatory patch device designed to aid in detecting ischemia and complex arrhythmias
- Study will enroll approximately 50 patients with a high risk of coronary artery disease whose resting ECGs show no evidence of ischemia
- Results will help inform Company’s broader regulatory strategy for the HeartBeam patch

Strategic Partnership Conversations Continue to Advance

- Significant level of interest in a collaboration
- ACC and HRS conferences provided opportunity for face-to-face meetings

Multiple Entry Points Into A Patient's Care Continuum

- More frequent symptoms
- Need to quantify arrhythmia burden
- Extended monitoring requested

Need for deeper clinical insight

EPISODIC MONITORING

HeartBeam System (Card)

- Patient uses card for peace of mind
- Gets MD input as symptoms occur

Long-term cardiac management

- Monitor Intermittent arrhythmias over lifetime
- Negative patch, symptoms or anxiety persists
- High-risk patients

CONTINUOUS MONITORING

HeartBeam On-Demand 12L Patch

- Extended monitoring with 12-lead capability
- Post-procedure (MI, ablation, etc.)

On-demand 12-Lead Patch and Ischemia products not cleared by FDA and not available for sale in the United States or other geographies.

Heart Attack Detection

Clinical-grade heart attack detection, available wherever patients are.



20M+ **high-risk patients in the U.S.**

Problem

Patients can’t recognize a heart attack at home

12-Lead ECG is only in hospitals

3–4 hour delays = death or heart failure

Why We Win

Two proof of concept studies show HeartBeam is similar to standard 12-Lead ECG

Baseline ECG improves accuracy over single ECG

Same device → expanded indication (no new hardware)

Status

ALIGN-ACS Pilot study underway with patient enrollment pacing ahead of schedule

ED design accelerates timelines (not prescribing to patients and waiting for events)

Informs pivotal study design

De Luca G. Circulation. 2004 Mar 16;109(10):1223-5 Heidenreich PA, J Card Fail. 2022 Mar;28(3):453-466.
Ischemia product not cleared by FDA and not available for sale in the United States or other geographies.

HeartBeam Vision for Heart Attack Detection

Physician augmented by deep learning algorithm with insights into STEMI and NSTEMI

Patient

ECG Data

ECG Interpretation and recommended action

With Cloud-Based AI Interpretation of ECG

Cardiologist reviews:
- ECG
- Baseline ECG
- Symptoms
- Patient history
- **AI output including STEMI/NSTEMI insights**

Upcoming Milestones

Continued progress on commercialization and other major corporate initiatives

	Q1 26	Q2 26	Q3 26	Q4 26	2027-
12-LEAD LIMITED LAUNCH 	✓ 12-LEAD FDA CLEARANCE ✓ CCO HIRE	✓ VALIDATE PREMIUM POSITIONING ✓ SIGN/ONBOARD INITIAL ACCOUNTS	ESTABLISH FUNNEL FOR 2027 GOALS DEVELOP PROOF POINTS FOR ADOPTION EXPAND COMMERCIAL TEAM		SCALE REVENUE FURTHER EXPAND TEAM
HEART ATTACK DETECTION 	✓ INITIATE ALIGN-ACS STUDY	INITIATE HEADSTART-ACS STUDY	COMPLETE ALIGN-ACS	FINALIZE FDA PIVOTAL STUDY DESIGN	CONDUCT ALIGN-ACS II PIVOTAL STUDY
12-LEAD PATCH 	✓ COMPLETE DEVELOPMENT OF PATCH WORKING PROTOTYPE	PARTNERSHIP DISCUSSIONS ✓ INITIATE PILOT STUDY	COMPLETE PILOT STUDY		COLLABORATE ON CLINICAL AND REGULATORY PATHWAY
ARTIFICIAL INTELLIGENCE 	✓ FINALIZE MT SINAI COLLABORATION	DEVELOP AI WELLNESS AND MI DETECTION MODELS		FDA CLEARANCE OF ARRHYTHMIA ALGORITHM	DELIVER ADDITIONAL ALGORITHMS

Heart attack detection, AI algorithm, and 12-Lead patch products not cleared by FDA and not available for sale in the United States or other geographies.

Balance Sheet Strengthened with Recent Offering

- Gross proceeds of $11.5 million
    - Closed a $10.0 million underwritten public offering of common stock on April 16, 2026
    - Closed the $1.5 million overallotment in May 2026
- Round led by first commercial customer, ClearCardio; alongside our executive leadership, board members, existing investors, and several fundamental institutional investors
- $12.4 million proforma cash balance as of March 31, 2026 provides cash runway to advance HeartBeam into our next phase of growth
- Focused on minimizing further dilution to shareholders

	YEAR-OVER-YEAR QUARTERLY CHANGE		**QUARTER-OVER-QUARTER CHANGE**	
	Quarter Ended March 31,		**Quarter Ended**	
$ in Thousands	2026[i]	2025	March 31, 2026[i]	Dec. 31, 2025
Cash, cash equivalents and restricted cash[ii]	$ 2,095	$ 8,150	$ 2,095	$ 4,436
Estimated net proceeds from capital raise[iii]	$ 10,330		$ 10,330	
Proforma Cash Balance[iii]	**$ 12,425**	**$ 8,150**	**$ 12,425**	**$ 4,436**

i. Refer to the Form 10-Q unaudited financial statements for the quarter ended March 31, 2026
ii. Includes restricted cash of $56k in all periods.
ii. Estimated Net Proceeds from the Offering and Overallotment between April 2026 – May 2026

Continued Financial Discipline Focused on Achieving Milestones

- Net cash used in operating activities of $3.6M in Q1 2026.
  - **19% decrease compared to same quarter prior year.**
  - Spend and EPS ahead of expectations.
  - Includes investments in commercial launch and 12-lead Patch development.
- Continued judicious timing of investments providing ability to maintain low cost profile.
  - Operating cash outflow expected to be below $16.0M in 2026, reduced from the $17.0M-$19.0M range previously guided to.
  - Cash receipts from customers in second half of year will provide further reduction to cash burn.

	YEAR-OVER-YEAR QUARTERLY CHANGE		QUARTER-OVER-QUARTER CHANGE	
	Quarter Ended March 31,		Quarter Ended	
$ in Thousands	2026[i]	2025	March 31, 2026[i]	Dec. 31, 2025
Operating Expenses:				
Selling, general & administrative	$ 2,346	$ 2,012	$ 2,346	$ 1,956
Research & development	2,370	3,492	2,370	3,354
Total operating expenses	4,716	5,504	4,716	5,310
Loss from operations	(4,716)	(5,504)	(4,716)	(5,310)
Interest and other expense (net)	16	20	16	8
Net Loss	**$ (4,700)**	**$ (5,484)**	**$ (4,700)**	**$ (5,302)**
Earnings per Share (EPS)	$ (0.12)	$ (0.18)	$ (0.12)	$ (0.15)
Net Loss	$ (4,700)	$ (5,484)	$ (4,700)	$ (5,302)
Less non-cash items and timing differences	1,090	1,007	1,090	2,396
Net cash used in operating activities[i]	**$ (3,610)**	**$ (4,477)**	**$ (3,610)**	**$ (2,906)**

i. Refer to the Form 10-Q unaudited financial statements for the quarter ended March 31, 2026
ii. Net cash used in operating activities is calculated as Net loss, less non-cash items such as stock-based compensation and timing differences.

Summary

Executing on a $40B Cardiac Monitoring Platform Opportunity

- Significantly de-risked technology
  - First ever FDA-cleared, cable-free synthesized 12-Lead ECG for arrhythmia assessment
  - Strong IP and clinical evidence
- Balance sheet strengthened with April 2026 Offering
  - Capital-efficient strategy; judicious timing of investments
- Multiple value creation opportunities in 2026:

Limited Commercial Launch

- Built flagship account presence in New York, Dallas, South Florida and Southern California
- Cost-effective expansion strategy does not require large sales force

Heart Attack Detection

- Rapidly advancing clinical validation to support indication expansion into acute ischemia/heart attack detection
- ALIGN-ACS pilot study enrolling ahead of schedule

On-Demand 12-Lead Patch

- Best in class product in $2B revenue market with existing reimbursement
- Initiated Pilot Study; exploring strategic partnerships to speed adoption

AI Algorithms

- Developing next generation algorithms, including wellness and MI detection
- Partnering with Mt Sinai to bring 12-Lead screening and predictive algorithms to the HeartBeam System

Q&A

Company
Tim Cruickshank
CFO
HeartBeam, Inc.
ir@heartbeam.com

Investor Relations
Chris Tyson
Executive Vice President
MZ North America
Direct: 949-491-8235
BEAT@mzgroup.us
www.mzgroup.us

www.heartbeam.com

2118 Walsh Avenue, Suite 210
Santa Clara, CA 95050